Izberite preskusne funkcije, ki jih želite preveriti.

Dokument je izvleček s spletišča EUR-Lex.

Dokument 62024TB0666

Case T-666/24 R: Order of the President of the General Court of 27 March 2025 – Teva Pharma v EMA (Interim relief – Access to documents – Regulation (EC) No 1049/2001 – Documents relating to the EMA’s scientific advice given pursuant to Article 57(1)(n) of Regulation (EC) No 726/2004 – Decision to grant a third party access to the documents – Application for suspension of operation of a measure – No urgency)

OJ C, C/2025/2557, 12.5.2025, ELI: http://data.europa.eu/eli/C/2025/2557/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

ELI: http://data.europa.eu/eli/C/2025/2557/oj

European flag

Official Journal
of the European Union

EN

C series


C/2025/2557

12.5.2025

Order of the President of the General Court of 27 March 2025 – Teva Pharma v EMA

(Case T-666/24 R)

(Interim relief - Access to documents - Regulation (EC) No 1049/2001 - Documents relating to the EMA’s scientific advice given pursuant to Article 57(1)(n) of Regulation (EC) No 726/2004 - Decision to grant a third party access to the documents - Application for suspension of operation of a measure - No urgency)

(C/2025/2557)

Language of the case: English

Parties

Applicant: Teva Pharma BV (Haarlem, Netherlands) (represented by: C. Lindenthal and A. Säurig, lawyers)

Defendant: European Medicines Agency (represented by: G. Gavriilidou, S. Drosos and G. Ramo, acting as Agents)

Re:

By its application based on Articles 278 and 279 TFEU, the applicant seeks suspension of the operation of Decision EMA/391476/2024 Rev.1 of the European Medicines Agency (EMA) of 28 October 2024 granting a third party, under Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to a document relating to scientific advice concerning the medicinal product ferric carboxymaltose, subject to certain redactions.

Operative part of the order

1.

The application for interim measures is dismissed.

2.

The order of 30 December 2024, Teva Pharma v EMA (T-666/24 R), is cancelled.

3.

The costs are reserved.


ELI: http://data.europa.eu/eli/C/2025/2557/oj

ISSN 1977-091X (electronic edition)


Na vrh